drugset / Trial / NCT02358018
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Summary
The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor. 68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the USA, with better tumor detection than with OctreoScan.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATOC | Peptide | 10 ug | Intravenous |
| Subject | 68Ga-DOTATOC | Peptide | 50 ug | Intravenous |
| Subject | 68Ga-DOTATOC | Peptide | 111 mbq | Intravenous |
| Subject | 68Ga-DOTATOC | Peptide | 203.5 mbq | Intravenous |